SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-255708
Filing Date
2022-09-30
Accepted
2022-09-30 17:13:13
Documents
13
Period of Report
2022-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d376662d8k.htm   iXBRL 8-K 30322
  Complete submission text file 0001193125-22-255708.txt   183459

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lgnd-20220930.xsd EX-101.SCH 3229
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lgnd-20220930_def.xml EX-101.DEF 13395
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE lgnd-20220930_lab.xml EX-101.LAB 21962
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lgnd-20220930_pre.xml EX-101.PRE 14193
7 EXTRACTED XBRL INSTANCE DOCUMENT d376662d8k_htm.xml XML 4984
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 221284902
SIC: 2834 Pharmaceutical Preparations